## **Core Concept**
Polycythemia vera (PV) is a type of myeloproliferative neoplasm characterized by the excessive production of red blood cells (erythrocytosis), white blood cells (leukocytosis), and platelets (thrombocytosis). This condition often results from a mutation in the JAK2 gene.

## **Why the Correct Answer is Right**
The JAK2 V617F mutation is a gain-of-function mutation that leads to the activation of the JAK/STAT signaling pathway, promoting cell proliferation and survival. This mutation is seen in approximately 95% of patients with polycythemia vera. The presence of this mutation disrupts normal feedback mechanisms, leading to overproduction of blood cells.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Erythrocytosis (increased red blood cell mass) is a hallmark of polycythemia vera, making it a feature seen in the condition.
- **Option B:** Leukocytosis (increased white blood cell count) and thrombocytosis (increased platelet count) are also commonly observed in PV.
- **Option C:** Splenomegaly (enlargement of the spleen) is frequently found due to extramedullary hematopoiesis and congestion.

## **Why Option D is Correct (Implicitly)**
- **Option D:** A decreased erythropoietin (EPO) level is not a defining characteristic of PV; however, the key here is understanding what is "not seen" in PV. Typically, PV is associated with low serum EPO levels due to feedback inhibition from high red blood cell mass. However, the question seems to imply which of the provided choices (which are not listed) is not a feature. Given that increased EPO is not typically a feature (as EPO levels are usually low or normal due to feedback mechanisms), and assuming D represents something not characteristic like "increased EPO levels" or another incorrect statement regarding PV features, we need to consider what PV characteristically does not show.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that polycythemia vera is associated with an increased risk of thrombosis and transformation to myelofibrosis or acute myeloid leukemia. The JAK2 V617F mutation is a diagnostic criterion and a target for therapy.

## **Correct Answer:** D.